Emerging CD123-Targeted Therapies for BPDCN: Pivotal Trial Insights and Future Potential

Dr. Andrew Lane discusses CD123-targeted therapies, particularly the antibody-drug conjugate pivekimab sunirine (PVEK), for treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). He notes PVEK's promising response rates and safety profile from early trial data, including lower risk of concerning side effects like capillary leak syndrome that can occur with the currently approved CD123-targeting agent tagraxofusp. In closing, he emphasizes accurately diagnosing BPDCN via expert hematopathology review and referral to specialized centers taking a cross-disciplinary approach, as combining emerging CD123-directed therapies with stem cell transplant as appropriate gives the best chance for optimal BPDCN management.

EP: 1.Diagnosing Blastic Plasmacytoid Dendritic Cell Neoplasm

EP: 2.BPDCN: A Multidisciplinary Approach to Diagnosis and Treatment

EP: 3.Pivekimab Sunirine: A Novel CD123 ADC Showing Promise for BPDCN

EP: 4.Advances in Diagnosis and Targeted Therapies for BPDCN from an Expert Dermatopathologist

Now Viewing

EP: 5.Emerging CD123-Targeted Therapies for BPDCN: Pivotal Trial Insights and Future Potential

Related Videos